Tvardi Therapeutics' update on Phase 2 Revert trial in Idiopathic Pulmonary Fibrosis
ReutersOct 13, 2025 11:36 AM
Oct 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O:
TVARDI THERAPEUTICS PROVIDES UPDATE ON PRELIMINARY DATA FROM PHASE 2 REVERT TRIAL IN IDIOPATHIC PULMONARY FIBROSIS
TVARDI THERAPEUTICS INC - STUDY DID NOT MEET ITS GOALS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
UK August GDP: Economy & Assets—Set to Collapse?
TradingKey - The UK is scheduled to release its August GDP figures on 16 October, with the market widely anticipating a 0.1% month-on-month increase in real GDP (Figure 1). If this expectation is fulfilled, it will represent the UK economy’s third consecutive month of recovery, following two straighTradingKey
4 hours ago
U.S. Banks Q3 Earnings Preview: Big 5 Banks See Double-Digit EPS Growth, Investment Banking Hits 4-Year High
TradingKey - The 2025 U.S. earnings season kicks off this week with results from major banks. Amid elevated investor sentiment and the Trump administration pushing for deregulation, analysts expect another strong quarter for the banking sector — driven by booming trading activity and a resurgenceTradingKey
5 hours ago
U.S.–China Tariff Easing Sparks Crypto Rebound — Can Bitcoin Reclaim Its Peak?
The U.S. signals a softer stance on tariffs, helping Bitcoin reverse losses. Rate cut expectations may push BTC back toward $126,000.TradingKey
6 hours ago
FOMC October Meeting Minutes: How Should Investors Respond?
In the context of the U.S. government shutdown and a period of limited economic data, the Federal Reserve’s release of its latest monetary policy meeting minutes and officials’ statements on 8 October will be particularly significant.TradingKey
Tue, Oct 7
Broadcom Q3 FY2025 Earnings Review: AI Surge and VMware Synergy Fuel Record Performance
TradingKey - Broadcom Inc. (NASDAQ: AVGO) delivered a strong fiscal Q3 2025, with results driven by AI networking strength and continued VMware integration. Revenue and EPS both topped expectations, reinforcing the company’s role as an essential player in the AI infrastructure buildout.TradingKey
Fri, Sep 5
